Original title: First Detection of WHO-validated artemisinin resistance Plasmodium falciparum K13 C469Y mutation in patient from Senegal
Amy Gaye, Bassirou Ngom, Djiby Sow, Aita Sene +24 · September 2026
Doctors treat malaria with medicines called artemisinin-based combination therapies. Recently, the malaria parasite in Africa has started developing genetic changes, or mutations, that help it resist these drugs. To check for this threat, researchers ran a surveillance study across Senegal. They looked at the DNA of the parasites to track drug-resistant strains. Out of thousands of samples, they found one patient carrying a specific resistance mutation called K13 C469Y. This mutation made up about 15% of that patient's parasites, meaning it was mixed with normal ones. The patient had not traveled recently, which suggests they caught this resistant strain locally. Standard medicine still cured the infection completely, and no other samples carried validated resistance mutations. Even though the treatment still worked this time, finding this drug-resistant strain for the first time in Senegal shows why health workers must keep testing parasite genetics to catch resistance early.
Imagine a gardener spraying a weed killer that usually works. Most weeds die, but one weed has a tiny genetic change that makes it slightly resistant. That weed survives and could spread its resistance to others. In this paper, scientists found a single malaria parasite with a similar genetic change that makes it partially resistant to the main malaria drug, even though the patient still got better. This is the first time such a change has been seen in Senegal, so it's a warning sign.
Malaria patients in Senegal rely on artemisinin-based drugs to cure the infection. This finding shows that a resistance mutation has arrived locally, not just from travel. If it spreads, the standard treatment could stop working, making surveillance essential to stay ahead.
The mutation was found in only one sample, as a minority variant (15% allele frequency), and the patient recovered fully with standard treatment, so there is no evidence of clinical treatment failure. The study does not establish whether this mutation will spread or cause treatment failures in the future. It also does not cover all regions of Senegal equally, and the sample size of 3,800 may miss other rare mutations.
Ask anything about this paper. Answers come from its abstract, and say so when the abstract doesn't cover your question.
First Detection of WHO-validated artemisinin resistance Plasmodium falciparum K13 C469Y mutation in patient from Senegal — Amy Gaye, Bassirou Ngom, Djiby Sow et al. — medRxiv — doi:10.64898/2026.09.11.26362519
Abstract licence: CC BY
Explanation generated by Synthesis from the abstract — it is not the original paper. This is a preprint, so it hasn't necessarily been peer reviewed.